This English translation is made for reference purposes only, and in case of any discrepancies between this translation and the Japanese original, the original shall prevail.

Securities Code: 9273
(Dispatch date) September 7, 2026
(Start date of measures for electronic provision) August 28, 2026

To Our Shareholders:

Toshiyuki Shuto
President and Representative Director
KOA SHOJI HOLDINGS Co., Ltd.
7-13-15, Hiyoshi, Kohoku-ku, Yokohama-shi, Kanagawa, Japan

NOTICE OF THE 12th ANNUAL GENERAL MEETING OF SHAREHOLDERS

KOA SHOJI HOLDINGS Co., Ltd. (the "Company") is pleased to announce that its 12th Annual General Meeting of Shareholders for the business term ended June 30, 2026, will be held as described below.
Upon the convocation of the Annual General Meeting of Shareholders, we have taken electronic provision measures for the information (electronic provision items) regarding the contents of the Annual General Meeting of Shareholders reference materials, etc. We have posted this information on the following websites on the internet, and kindly ask you to access any of these websites and confirm the information.

[Our Company Website]
https://www.koashoji-hd.com/ir/meeting.html

[Tokyo Stock Exchange Website (TSE Listed Company Information Service)]
https://www2.jpx.co.jp/tseHpFront/JJK010010Action.do?Show=Show

Please access the above-mentioned Tokyo Stock Exchange website, enter "Koa Shoji Holdings" in the "Stock Name (Company Name)" or our securities code '9273' in the 'Stock Code' field, and search. Then, select "Basic Information" followed by "Document for Public Inspection/PR Information," and finally, please check the "Document for Public Inspection" section for the "Notice of General Meeting of Shareholders/Shareholder Meeting Materials."

Please note that if you are unable to attend the meeting in person, you can exercise your voting rights via the internet or in writing (by mail). We kindly ask you to review the General Meeting of Shareholders reference materials and exercise your voting rights by following the instructions provided below by no later than 5:30 p.m. on September 24, 2026 (Thursday) (Japan Standard Time).

1. Date and Time: 10 a.m. on September 25, 2026 (Friday) (Reception begins at 9:30 a.m.) (Japan Standard Time)

2. Venue: Hotel New Grand
("Rainbow Ball Room," 2nd floor of the main building)
10, Yamashita-cho, Naka-ku, Yokohama-shi, Kanagawa, 231-8520 Japan

3. Purposes

Matters to Report:

1. The Business Report and Consolidated Financial Statements for the 12th Fiscal Year (from July 1, 2025 to June 30, 2026), and the Report on the Results of Audit of the Consolidated Financial Statements by the Accounting Auditors and Audit & Supervisory Committee

2. Non-Consolidated Financial Statements for the 12th Fiscal Year (from July 1, 2025 to June 30, 2026)

Matters for Resolution:

Proposal 1: Appropriation of Surplus

Proposal 2: Election of Six (6) Directors (Excluding Directors who are Audit & Supervisory Committee Members)

Proposal 3: Election of One (1) Director who is Audit & Supervisory Committee Member

Proposal 4: Presentation of Retirement Bonus to Retiring Director

◎ When you attend the meeting, we kindly request that you submit the voting form to our receptionist at the venue.

◎ If any amendments are made to the electronic provision items, the revised information, as well as the original information, will be posted on the respective websites mentioned on the previous page.

◎ Among the items subject to electronic provision measures, the following items are not included in the documents provided to shareholders who have requested written documents, in accordance with the provisions of laws and our Articles of Incorporation. Please note the Audit & Supervisory Committee and Accounting Auditors audit documents that include the following items.
  (1) "Status of Accounting Auditors," "Overview of the System for Ensuring the Appropriateness of Business Operations and Its Operational Status," and "Basic Policy on Control over the Company" in the Business Report.
  (2) "Consolidated Statement of Changes in Shareholders' Equity" and "Notes to the Consolidated Financial Statements" in the Consolidated Financial Statements.
  (3) "Non-Consolidated Statement of Changes in Shareholders' Equity" and "Notes to the Non-Consolidated Financial Statements" in the Non-Consolidated Financial Statements.

◎ The Company <u>will not distribute any souvenirs</u> at the General Meeting of Shareholders in consideration of fairness to shareholders who are unable to attend the meeting.

Acceptance of Questions in Advance

The Company accepts questions regarding the purposes of the General Meeting of Shareholders. On the day of the General Meeting of Shareholders, the Company will respond to questions that are deemed to be of high interest to shareholders.
Please note that the Company will not answer questions individually.

Deadline for submission of questions	5:30 p.m., September 16, 2026 (Wednesday)
How to submit questions	Please submit your questions via the following URL. https://forms.cloud.microsoft/r/z4LHmvyfaq

Reference Documents for the General Meeting of Shareholders

Proposal 1: Appropriation of Surplus

The Company considers the return of profits to shareholders as one of its most important management priorities and is committed, in principle, to increasing dividends every year. However, taking into account the earnings prospects and future business deployment, we would like to declare appropriation of surplus for the 12th fiscal year under review as described below.

Matters related to year-end dividends

(1) Type of dividend assets
    Cash

(2) Allotment of dividend assets to shareholders and the amount thereof
    JPY 18 per share of common stock of the Company
    Total: JPY 758,133,072

(3) Date when the appropriation of surplus becomes effective
    September 28, 2026

(For Reference) Trends in Dividend per Share



Note: The above table has been calculated taking into account the effects of stock splits conducted to date.

Proposal 2: Election of Six (6) Directors (Excluding Directors who are Audit & Supervisory Committee Members)

The term of office of all Directors (excluding Directors who are Audit & Supervisory Committee Members) will expire at the closing of this General Meeting of Shareholders. Therefore, it is proposed that six (6) candidates be elected.

In order to enhance the fairness, transparency, and objectivity of procedures related to the nomination and remuneration of Directors, and to strengthen corporate governance, the Company has established a voluntary Nomination and Remuneration Advisory Committee, which is composed of a majority of Independent Outside Directors. The selection of director candidates is determined through deliberations and recommendations by this committee.

The Audit & Supervisory Committee has determined that all of the candidates are qualified for the Board of Directors.

The candidates for Directors are as follows:

No.	Name	Current Position and Responsibility		Attendance at the Meetings of the Board of Directors	Tenure
1	Toshiyuki Shuto	President and Representative Director	Reappointment	14 out of 14 (100%)	11 years
2	Ritsuko Ohtsuka	Director and Executive Vice President Sustainability Officer and in charge of API Sales Business	Reappointment	14 out of 14 (100%)	11 years
3	Toshihiro Hirono	Director and Executive Vice President In charge of Pharmaceutical Manufacturing and Sales Business	Reappointment	13 out of 14 (92%)	11 years
4	Miyoko Komatsu	Managing Director In charge of Finance & Accounting	Reappointment	14 out of 14 (100%)	10 years
5	Teruyuki Tanaka	Director In charge of Business Development/Corporate Planning	Reappointment	14 out of 14 (100%)	8 years
6	Hideyuki Isoda	-	New	-	-

(Note) The tenure is the number of years at the conclusion of this General Meeting of Shareholders, rounded down to the nearest year.

Reappointment: Candidate for reappointment as Director

New: Candidate for new Director

Candidate No.	Name (date of birth)	Brief profile, position and responsibility in the Company (status of important concurrent positions)	
1	Toshiyuki Shuto (March 1, 1947) Reappointment Male Attendance at the Meetings of the Board of Directors 14/14 (100%) Tenure: 11 years	Jan. 1972	Joined Nippon Montedison K.K.
		Mar. 1975	Transferred to Zanbon Co., Ltd. JAPAN
		Feb. 1991	Established KOA SHOJI CO., LTD. Director of the company
		Aug. 1994	Vice President of the company
		Aug. 1995	President, Representative Director of the company
		Jul. 2011	Director of KOA ISEI CO., LTD.
		Aug. 2013	Chairperson, Representative Director of KOA SHOJI CO., LTD.
		Jan. 2015	President, Representative Director of the Company (to present)
		Aug. 2015	Chairperson, Representative Director of KOA BIOTECH BAY CO., LTD.
		Sep. 2016	Chairperson & President, Representative Director of KOA ISEI CO., LTD.
		Sep. 2016	Chairperson, Representative Director of KOA PHARMACEUTICAL CO., LTD. (absorbed and merged with KOA BIOTECH BAY)
		Sep. 2018	Chairperson & President, Representative Director of KOA SHOJI CO., LTD.
		Sep. 2018	Chairperson, Representative Director of KOA ISEI CO., LTD. (to present)
		Sep. 2018	Chairperson & President, Representative Director of KOA BIOTECH BAY CO., LTD.
		Sep. 2019	Chairperson, Representative Director of KOA BIOTECH BAY CO., LTD.
		Sep. 2020	Chairperson & President, Representative Director of KOA PHARMACEUTICAL CO., LTD. (absorbed and merged with KOA BIOTECH BAY)
		Sep. 2021	Chairperson, Representative Director of KOA SHOJI CO., LTD. (to present)
		Sep. 2021	Chairperson, Representative Director of KOA PHARMACEUTICAL CO., LTD. (absorbed and merged with KOA BIOTECH BAY)
		Oct. 2021	Establishment of the general incorporated association

			Shuto Scholarship Foundation (now the public interest incorporated foundation Shuto Scholarship Foundation) Representative Director of the foundation (to present)
		Sep. 2022	Advisor to KOA BIOTECH BAY CO., LTD. (to present)
		(Important concurrent positions) Chairperson, Representative Director of KOA SHOJI CO., LTD. Chairperson, Representative Director of KOA ISEI CO., LTD. Advisor to KOA BIOTECH BAY CO., LTD. Representative Director of the public interest incorporated foundation Shuto Scholarship Foundation	
	(Reasons for nominating the candidate for Director) Mr. Toshiyuki Shuto is the founder of the Company and a person who will drive the sustainable enhancement of the corporate value of the Group. Therefore, the Company is of the judgment that his achievements, capabilities, and experience will continue to be indispensable to the management of the Company.		
	(Number of the Company's shares owned) 2,108,273		

<table>
<tr><th>Candidate No.</th><th>Name
(date of birth)</th><th>Brief profile, position and responsibility in the Company
(status of important concurrent positions)</th></tr>
<tr><td rowspan="4">2</td><td rowspan="2">Ritsuko Ohtsuka
(February 1, 1978)

Reappointment

Female

Attendance at the Meetings of the Board of Directors
14/14 (100%)

Tenure: 11 years</td><td>Apr. 2008 Joined KOA SHOJI CO., LTD.
Jan. 2015 Director of the Company in charge of Scientific Div.
Aug. 2015 Director of KOA SHOJI CO., LTD.
Sep. 2016 Director of KOA BIOTECH BAY CO., LTD.
Sep. 2018 Director of KOA ISEI CO., LTD.
Sep. 2019 President, Representative Director of KOA BIOTECH BAY CO., LTD.
Sep. 2020 Managing Director of the Company in charge of Quality
Sep. 2021 President, Representative Director of KOA SHOJI CO., LTD. (to present)
Sep. 2021 Managing Director of the Company, Sustainability Officer
Sep. 2022 Chairperson, Representative Director of KOA BIOTECH BAY CO., LTD.
Sep. 2024 Director and Executive Vice President of the Company, Sustainability Officer
Sep. 2025 Director and Executive Vice President of the Company, Sustainability Officer, and in charge of API Sales Business (to present)</td></tr>
<tr><td>(Important concurrent positions)
President, Representative Director of KOA SHOJI CO., LTD.</td></tr>
<tr><td colspan="2">(Reasons for nominating the candidate for Director)
Ms. Ritsuko Ohtsuka has intimate knowledge of the generic pharmaceutical industry. The Company is of the judgment that her experience and insight as Director in charge of Sustainability and API Sales Business will continue to be indispensable for the Company’s management.</td></tr>
<tr><td colspan="2">(Number of the Company’s shares owned)
487,320</td></tr>
</table>

<table>
<tr><th>Candidate No.</th><th>Name
(date of birth)</th><th>Brief profile, position and responsibility in the Company
(status of important concurrent positions)</th></tr>
<tr><td rowspan="4">3</td><td rowspan="2">Toshihiro Hirono
(November 11, 1949)

Reappointment

Male

Attendance at the Meetings of the Board of Directors
13/14 (92%)

Tenure: 11 years</td><td>Aug. 1973 Joined Kobayashi Pharmaceutical Industries, Co., Ltd. (currently neo CritiCare Pharma Co., Ltd.)
Jun. 2002 Director of the company
Oct. 2007 Managing Director of the company
Apr. 2008 Executive Vice President of the company
Nov. 2014 Joined KOA SHOJI CO., LTD.
Corporate Advisor of the company
Jan. 2015 Director of the Company in charge of Manufacturing Engineering Div.
May 2016 Vice President of KOA ISEI CO., LTD.
Sep. 2018 Director of KOA BIOTECH BAY CO., LTD.
Sep. 2018 President, Representative Director of KOA ISEI CO., LTD. (to present)
Sep. 2024 Managing Director of the Company in charge of Production
Sep. 2025 Chairperson, Representative Director of KOA BIOTECH BAY CO., LTD. (to present)
Sep. 2025 Director and Executive Vice President of the Company in charge of Pharmaceutical Manufacturing and Sales Business (to present)</td></tr>
<tr><td>(Important concurrent positions)
President, Representative Director of KOA ISEI CO., LTD.
Chairperson, Representative Director of KOA BIOTECH BAY CO., LTD.</td></tr>
<tr><td colspan="2">(Reasons for nominating the candidate for Director)
Mr. Toshihiro Hirono is well versed in the generic pharmaceutical industry, and as Director in charge of Pharmaceutical Manufacturing and Sales Business, he has the ability to promote and execute the pharmaceutical manufacturing and sales business of the Group. Therefore, the Company is of the judgment that his achievements and capabilities will continue to be indispensable to the management of the Company.</td></tr>
<tr><td colspan="2">(Number of the Company’s shares owned)
10,000</td></tr>
</table>

<table>
<tr><th>Candidate No.</th><th>Name
(date of birth)</th><th colspan="2">Brief profile, position and responsibility in the Company
(status of important concurrent positions)</th></tr>
<tr><td rowspan="4">4</td><td rowspan="2">Miyoko Komatsu
(May 14, 1964)

Reappointment

Female

Attendance at the Meetings of the Board of Directors
14/14 (100%)

Tenure: 10 years</td><td>Sep. 1996
May 2000
Apr. 2005
Dec. 2006
Jul. 2015

Jan. 2016
Sep. 2016
Sep. 2016
Sep. 2018

Dec. 2020

Sep. 2021
Sep. 2025
Sep. 2025</td><td>Joined Ishii Tax Accountant Office
Joined Koyama CPA firm
Joined Pasona Inc.
Joined KOA SHOJI CO., LTD.
Transferred to the Company, General Manager for Finance
Financial Controller of the Company
Auditor of KOA BIOTECH BAY CO., LTD. (to present)
Director and Financial Controller of the Company
Director in charge of Finance Control and General Affairs and Financial Controller of the Company
Director in charge of Finance & Accounting and General Affairs
Director in charge of Finance & Accounting
Auditor of KOA SHOJI CO., LTD. (to present)
Managing Director in charge of Finance & Accounting (to present)</td></tr>
<tr><td colspan="2">(Important concurrent positions)
Auditor of KOA SHOJI CO., LTD.
Auditor of KOA BIOTECH BAY CO., LTD.</td></tr>
<tr><td colspan="3">(Reasons for nominating the candidate for Director)
Ms. Miyoko Komatsu has been in charge of Finance & Accounting over a period of time in the Company. Her experience and knowledge as Director in charge of Finance & Accounting are essential to the Company. Therefore, the Company is of the judgment that her experience and knowledge will continue to be indispensable to the management of the Company.</td></tr>
<tr><td colspan="3">(Number of the Company’s shares owned)
264,120</td></tr>
</table>

<table>
<tr><th>Candidate No.</th><th>Name
(date of birth)</th><th>Brief profile, position and responsibility in the Company
(status of important concurrent positions)</th></tr>
<tr><td rowspan="4">5</td><td rowspan="2">Teruyuki Tanaka
(January 3, 1950)

Reappointment

Male

Attendance at the Meetings of the Board of Directors
14/14 (100%)

Tenure: 8 years</td><td>Apr. 1972 Joined Nippon Kayaku Co., Ltd.
Aug. 1997 Manager, Sales Operation Dept. of the company
Jun. 2002 GE Strategic Manager of the Pharmaceutical Div. of the company
Sep. 2011 Joined Oishi Koseido Co., Ltd.
General Manager of the Sales Div. and Corporate officer of the company
Jul. 2017 Joined the Company
Manager of the Corporate Planning Div.
Sep. 2017 Executive Vice President, Director of KOA SHOJI CO., LTD.
Sep. 2018 Director of the Company, Manager of the Corporate Planning Div.
Jul. 2019 Director in charge of Business Development of the Company
(currently in charge of Business Development/Corporate Planning) (to present)</td></tr>
<tr><td>(Important concurrent positions)
-</td></tr>
<tr><td colspan="2">(Reasons for nominating the candidate for Director)
Mr. Teruyuki Tanaka has intimate knowledge of the generic pharmaceutical industry, and as Director in charge of Business Development and Corporate Planning he has the ability to execute business development for the Group’s growth. Therefore, the Company is of the judgment that his achievements and capabilities will continue to be indispensable to the management of the Company.</td></tr>
<tr><td colspan="2">(Number of the Company’s shares owned)
-</td></tr>
</table>

<table>
<tr><th>Candidate No.</th><th>Name (date of birth)</th><th colspan="2">Brief profile, position and responsibility in the Company (status of important concurrent positions)</th></tr>
<tr><td rowspan="12">6</td><td rowspan="11">Hideyuki Isoda
(May 4, 1970)

New

Male

Attendance at the Meetings of the Board of Directors
-

Tenure: -</td><td>Apr. 1995</td><td>Joined Taisho Yakuhin Kogyo Inc. (currently Takeda Pharmaceutical Company Limited)</td></tr>
<tr><td>Apr. 2012</td><td>Seconded to Teva Pharma Japan Inc. (currently T’s Pharma Co., Ltd.)
General Manager of the Solid Preparation Research Department of the Research & Development Division of the company</td></tr>
<tr><td>Jun. 2016</td><td>Joined KOA SHOJI CO., LTD.
General Manager of the Development Dept. II of the Development Div. of the company</td></tr>
<tr><td>Sep. 2016</td><td>General Manager of the Development Div. and General Manager of the Development Dept. II of the company</td></tr>
<tr><td>Sep. 2017</td><td>Corporate Officer, General Manager of the Development Div. and General Manager of the Development Dept. II of the company</td></tr>
<tr><td>Sep. 2019</td><td>Director in charge of Development, General Manager of the Development Div. and General Manager of the Development Div. II of the company</td></tr>
<tr><td>Jul. 2021</td><td>Director in charge of Development and General Manager of the Development Dept. of the company</td></tr>
<tr><td>Sep. 2021</td><td>Managing Director in charge of Development and General Manager of the Development Dept. of the company</td></tr>
<tr><td>Sep. 2025</td><td>Director, Executive Vice President in charge of Development and General Manager of the Development Dept. of the company (to present)</td></tr>
<tr><td colspan="2">(Important concurrent positions)
Executive Vice President, Director of KOA SHOJI CO., LTD.</td></tr>
<tr><td colspan="2"></td></tr>
<tr><td colspan="3">(Reasons for nominating the candidate for Director)
Mr. Hideyuki Isoda has a wealth of experience and extending knowledge he has cultivated in the development department for many years. Therefore, the Company is of the judgment that his achievements and capabilities will be indispensable to the management of the Company.

(Number of the Company’s shares owned)
-</td></tr>
</table>

Notes: 1. There are no special interests between any candidate and the Company.

2. The candidate Ms. Ritsuko Ohtsuka is the daughter of the Company's Representative Director and President Mr. Toshiyuki Shuto.
3. The Company has entered into a liability insurance agreement with an insurance company for directors, corporate auditors, and managers of the Company and its group companies as insured parties, as provided in Article 430-3, Paragraph 1 of the Companies Act. In the event that a claim for damages is made by a shareholder, a company, or other third party arising out of the business of the insured, the Company will pay the relevant damages. In the event that the appointment of each candidate is approved, they will be included in the insured of the relevant insurance policy and the policy will be renewed with the same content at the next renewal.

Proposal 3: Election of One (1) Director who is Audit & Supervisory Committee Member

The term of office of Director who is Audit & Supervisory Committee Member, Mr. Hiroshi Kinoshita, will expire at the conclusion of this General Meeting of Shareholders.
Therefore, it is proposed that one (1) candidate be elected.
This proposal has been approved by the Audit & Supervisory Committee.
The candidate for Director who is Audit & Supervisory Committee Member is as follows:

Name	Current Position and Responsibility		Attendance at the Meetings of the Board of Directors	Attendance at the Meetings of the Audit & Supervisory Committee	Tenure
Hiroshi Kinoshita	Director who is Audit & Supervisory Committee Member	Reappointment Outside Independent	14 out of 14 (100%)	14 out of 14 (100%)	4 years

(Note) The tenure is the number of years at the conclusion of this General Meeting of Shareholders, rounded down to the nearest year.

Reappointment: Candidate for reappointment as Director
Outside: Candidate for Outside Director
Independent: Independent Director based on the provisions of the Tokyo Stock Exchange

Name (date of birth)	Brief profile, position and responsibility in the Company (status of important concurrent positions)	
Hiroshi Kinoshita (April 18, 1968) Reappointment Outside Independent Male Attendance at the Meetings of the Board of Directors 14/14 (100%) Attendance at the Meetings of the Audit & Supervisory Committee 14/14 (100%) Tenure: 4 years	Oct. 1992	Joined Asahi Shinwa Accounting Corporation (currently KPMG AZSA LLC)
	Apr. 1996	Registered as a certified public accountant
	May 2008	Partner, KPMG AZSA & Co. (currently KPMG AZSA LLC)
	Dec. 2019	Established Hiroshi Kinoshita Certified Public Accountant Office
	Mar. 2020	Director, Executive Officer and General Manager of the Operations Division, T&S Inc. (currently T&S Group Inc.)
	Sep. 2022	Outside Director (Audit & Supervisory Committee Member) of the Company (to present)
	Dec. 2023	Director, Executive Officer, COO, General Manager of Corporate HQ of T&S Inc. (currently T&S Group Inc.)
	Jun. 2024	Director, Executive Officer, and COO of T&S Group Inc. (to present)
	(Important concurrent positions) Certified public accountant Director, Executive Officer, and COO of T&S Group Inc.	
(Reasons for nomination as a candidate for Outside Director who is an Audit & Supervisory Committee Member and summary of expected roles) Mr. Hiroshi Kinoshita has a wealth of experience as a certified public accountant and possesses specialized insights in all aspects of finance and accounting. Based on his experience and expertise, we have nominated him as a candidate for Outside Director who is an Audit & Supervisory Committee Member. We expect him to provide advice and supervision on improvement of transparency and objectiveness of the management from an objective standpoint independent of the management team. If he is elected, he will continue to be involved in the selection of candidates for Director and decision on remuneration for executives as a member of the Nomination and Remuneration Advisory Committee from an independent and objective standpoint.		
(Number of the Company's shares owned) 400		

Notes: 1. There are no special interests between the candidate and the Company.

2. Mr. Hiroshi Kinoshita is a candidate for Outside Director who is Audit & Supervisory Committee

Member.

3. Mr. Hiroshi Kinoshita currently serves as Outside Director who is Audit & Supervisory Committee Member, and his tenure will be four (4) years at the conclusion of this General Meeting.
4. The Company has entered into a liability insurance agreement with an insurance company for directors, corporate auditors, and managers of the Company and its group companies as insured parties, as provided in Article 430-3, Paragraph 1 of the Companies Act. In the event that a claim for damages is made by a shareholder, a company, or other third party arising out of the business of the insured, the Company will pay the relevant damages. In the event that the reappointment of Mr. Hiroshi Kinoshita is approved, he will continue to be insured under the relevant insurance policy. The policy will be renewed with the same terms and conditions at the next renewal.
5. We have designated Mr. Hiroshi Kinoshita as an Independent Director based on the provisions of the Tokyo Stock Exchange and have submitted the necessary documentation. If his reappointment is approved, he will continue to serve as an Independent Director.

■ Reference: Structure of Board of Directors and Areas of Particular Expectation for Directors (Skills Matrix)

If proposals No. 2 and No. 3 are approved at this General Meeting of Shareholders as proposed, the following are the planned structures of the Board of Directors and the areas of particular expectation for Directors after this General Meeting of Shareholders.

Name	Position in the Company	Gender	Age	Areas of particular expectation for Directors					
				Corporate management	Sales and marketing	Finance and accounting	Legal affairs	Knowledge of the industry	Sustainability
Toshiyuki Shuto	President and Representative Director	Male	79	●	●			●	
Ritsuko Ohtsuka	Director and Executive Vice President	Female	48	●				●	●
Toshihiro Hirono	Director and Executive Vice President	Male	76	●				●	
Miyoko Komatsu	Managing Director	Female	62			●			●
Teruyuki Tanaka	Director	Male	76	●	●			●	
Hideyuki Isoda	Director	Male	56					●	
Yoshitaka Hirao	Director who is an Audit & Supervisory Committee Member (Independent, Outside)	Male	72	●	●			●	●
Hiroshi Kinoshita	Director who is an Audit & Supervisory Committee Member (Independent, Outside)	Male	58	●		●			
Kyoko Hayashi	Director who is an Audit & Supervisory Committee Member (Independent, Outside)	Female	59	●					●
Yuki Yamagishi	Director who is an Audit & Supervisory Committee Member (Independent, Outside)	Male	47				●		

Ratio of Outside Directors



Ratio of Female Directors



Proposal 4: Presentation of Retirement Bonus to Retiring Director

The Company proposes awarding a retirement bonus to Mr. Toshinori Koyama, Director (excluding Directors who are Audit & Supervisory Committee Members; hereafter the same shall apply for this proposal), who will retire upon the expiration of his term of office at the conclusion of this General Meeting, in recognition of his contributions during his tenure. This will be made in accordance with the Company's certain standards and within an appropriate amount.
The specific amount, timing, and method of presentation are to be determined at the discretion of the Board of Directors.
The Company considers this proposal appropriate as it has been determined by the Board of Directors after the deliberation by the Nomination and Remuneration Advisory Committee in line with the policy to determine details of remuneration for individual directors and the regulations on retirement bonuses for executives, which have been pre-established by the Board of Directors. The Company has also received an opinion from the Audit & Supervisory Committee that there are no significant issues to be pointed out regarding this proposal.
A brief profile of the retiring Director is as follows.

Name	Brief profile	
Toshinori Koyama	Jan. 2015	Director of the Company
	Sep. 2016	Executive Managing Director of the Company (to present)